{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T10:23:24Z","timestamp":1704277404115},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.imlet.2013.08.002","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T16:35:24Z","timestamp":1376584524000},"page":"18-24","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A new recombinant immunotoxin hscFv-ETA\u2019 demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro"],"prefix":"10.1016","volume":"154","author":[{"given":"Xiaoying","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2013.08.002_bib0005","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.08.002_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2013.08.002_bib0015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.imlet.2013.08.002_bib0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.imlet.2013.08.002_bib0025","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1021\/bc020033z","article-title":"Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery","volume":"14","author":"Safavy","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.imlet.2013.08.002_bib0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","article-title":"Antibody-drug conjugates for cancer therapy","volume":"14","author":"Carter","year":"2008","journal-title":"Cancer J"},{"key":"10.1016\/j.imlet.2013.08.002_bib0035","first-page":"115","article-title":"Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen","volume":"59","author":"Stan","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2013.08.002_bib0040","first-page":"6310","article-title":"Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor","volume":"52","author":"Wels","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2013.08.002_bib0045","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s00268-002-4064-2","article-title":"Application of molecular biology studies to gene therapy treatment strategies","volume":"26","author":"Gustin","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.imlet.2013.08.002_bib0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.leu.2401663","article-title":"Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate","volume":"14","author":"Bernstein","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.imlet.2013.08.002_bib0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1385\/MB:18:3:251","article-title":"Chemical construction of immunotoxins","volume":"18","author":"Ghetie","year":"2001","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.imlet.2013.08.002_bib0060","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1517\/14656566.1.6.1117","article-title":"Immunotoxins","volume":"1","author":"Kreitman","year":"2000","journal-title":"Expert Opin Pharmacother"},{"issue":"Pt 1","key":"10.1016\/j.imlet.2013.08.002_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/bj3070029","article-title":"Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor","volume":"307","author":"Kreitman","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.imlet.2013.08.002_bib0070","first-page":"3357","article-title":"Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma","volume":"55","author":"Kreitman","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2013.08.002_bib0075","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/1097-0215(20001215)88:6<970::AID-IJC21>3.0.CO;2-Q","article-title":"Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats","volume":"88","author":"Engebraaten","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.imlet.2013.08.002_bib0080","first-page":"1","article-title":"Recombinant single-chain immunotoxins against T and B cell leukemias","volume":"13","author":"Kreitman","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.imlet.2013.08.002_bib0085","doi-asserted-by":"crossref","first-page":"8616","DOI":"10.1073\/pnas.88.19.8616","article-title":"B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice","volume":"88","author":"Brinkmann","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.imlet.2013.08.002_bib0090","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/bjc.1996.448","article-title":"Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha","volume":"74","author":"Schmidt","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.imlet.2013.08.002_bib0095","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1128\/jb.170.2.714-719.1988","article-title":"Expression and secretion of the cloned Pseudomonas aeruginosa exotoxin A by Escherichia coli","volume":"170","author":"Lory","year":"1988","journal-title":"J Bacteriol"},{"key":"10.1016\/j.imlet.2013.08.002_bib0100","first-page":"1282","article-title":"Chimeric fusion proteins\u2014Pseudomonas exotoxin-based","volume":"2","author":"Kreitman","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.imlet.2013.08.002_bib0105","doi-asserted-by":"crossref","first-page":"24500","DOI":"10.1074\/jbc.M110.211847","article-title":"Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.imlet.2013.08.002_bib0110","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.imlet.2013.08.002_bib0115","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10529-012-0896-5","article-title":"Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells","volume":"34","author":"Wang","year":"2012","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.imlet.2013.08.002_bib0120","first-page":"939","article-title":"Expression of a humanized single-chain variable fragment antibody targeting chronic myeloid leukemia cells in Escherichia coli and its characterization","volume":"29","author":"Zhu","year":"2012","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.imlet.2013.08.002_bib0125","first-page":"523","article-title":"A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells","volume":"11","author":"Tur","year":"2003","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.imlet.2013.08.002_bib0130","doi-asserted-by":"crossref","first-page":"11830","DOI":"10.1158\/0008-5472.CAN-07-1160","article-title":"Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells","volume":"67","author":"Wang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2013.08.002_bib0135","first-page":"8737","article-title":"Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma","volume":"61","author":"Huhn","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2013.08.002_bib0140","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00262-002-0352-9","article-title":"Monoclonal antibody drug immunoconjugates for targeted treatment of cancer","volume":"52","author":"Trail","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.imlet.2013.08.002_bib0145","first-page":"249","article-title":"Construction and in vitro evaluation of RFT5(scFv)-ETA\u2019, a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines","volume":"1","author":"Barth","year":"1998","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.imlet.2013.08.002_bib0150","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2013.08.002_bib0155","first-page":"1179","article-title":"The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA\u2019 suppresses growth of a highly metastatic pancreatic carcinoma cell line","volume":"23","author":"Bruell","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/j.imlet.2013.08.002_bib0160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nm0396-350","article-title":"Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin","volume":"2","author":"Pai","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.imlet.2013.08.002_bib0165","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V81.9.2263.2263","article-title":"Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma","volume":"81","author":"Grossbard","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.08.002_bib0170","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.96.7.3957","article-title":"Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome","volume":"96","author":"Baluna","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.imlet.2013.08.002_bib0175","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V94.10.3340.422k19_3340_3348","article-title":"Responses in refractory hairy cell leukemia to a recombinant immunotoxin","volume":"94","author":"Kreitman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.08.002_bib0180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1615\/CritRevImmunol.v21.i1-3.200","article-title":"Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy","volume":"21","author":"Kawakami","year":"2001","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.imlet.2013.08.002_bib0185","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1349-7006.2009.01192.x","article-title":"Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy","volume":"100","author":"Mathew","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.imlet.2013.08.002_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00063030-200923010-00001","article-title":"Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies","volume":"23","author":"Kreitman","year":"2009","journal-title":"BioDrugs"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247813001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247813001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T00:40:43Z","timestamp":1596328843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247813001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0165247813001041"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2013.08.002","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new recombinant immunotoxin hscFv-ETA\u2019 demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2013.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}